By Olivia Hart

The EU has cleared Restylane Shaype for chin augmentation, moving a long-requested indication from off-label territory into the on-label toolkit for European aesthetic clinics.

The announcement, published by thedermdigest.com, is short on detail. It confirms only that a Restylane-branded injectable now carries an EU green light for chin projection and shaping — specifics on formulation, study cohort, and indication wording are not in the release.

What does the approval cover?

The source gives no granular breakdown. Clinicians should await the Summary of Product Characteristics for the formal scope — whether it covers projection only, projection and shape, full pogonion work, or pre-jowl sulcus correction.

The practical reading: chin augmentation with Shaype moves from off-label status to on-label across the EU's 27 member states.

Why now?

Chin augmentation has been one of the fastest-growing filler requests in European practices over the past three years. The trend tracks the broader "lower-face balancing" movement that emerged after the 2022 jawline and profile boom.

Most clinics have already offered the procedure, typically using higher-G' hyaluronic acid gels designed for structural placement. They have navigated the off-label conversation with patients at each visit.

A dedicated indication streamlines consent and may ease documentation friction in markets such as Germany, France, and the Nordics, where off-label aesthetic work sits outside reimbursement.

What does this change for day-to-day practice?

For most aesthetic dermatologists, the workflow shift is modest. The technical demands of chin augmentation — dense filler, careful mapping of the pogonion, conservative initial volume, and a four-to-six-week follow-up — remain unchanged.

What changes is the paperwork. Consent forms can reference an on-label indication, and adverse-event reporting can flow through a product-specific channel rather than a generic filler pathway.

Pricing is unlikely to move sharply. Chin augmentation across major EU markets currently runs €500–€900 per session, depending on volume, clinician credentialing, and clinic location.

What's the broader signal?

The Shaype clearance fits a regulatory pattern that has tightened over the past 18 months: site-specific filler indications are replacing the older "facial wrinkle" or "volume loss" framing.

European regulators have moved toward granular, site-specific claims as manufacturers push for differentiated positioning. The shift points to a more precise environment, one where clinicians match products to indications on the label rather than by clinical judgment alone.

What to watch

The published data behind the Shaype approval has not been detailed in the announcement. Clinicians considering adoption should look for the supporting trial — typically a prospective study of 100–200 subjects with six-to-twelve-month follow-up — to confirm duration, lift capacity, and safety profile in the chin specifically.

Real-world uptake over the next 12 to 18 months will determine whether Shaype becomes the default chin product in Europe or shares the category with established alternatives.